Ardelyx Bets Big On Tenapanor’s Potential, Despite Side Effect Concerns
This article was originally published in The Pink Sheet Daily
Executive Summary
Unwinding NHE3 partnership with AstraZeneca, Ardelyx plans to move first-in-class agent into Phase III in IBS-C while seeking more tolerable dosing regimen for late-stage development in hyperphosphatasia.
You may also be interested in...
Ardelyx Gets IBS-C Approval, But Focus Remains On Hyperphosphatemia
Tenapanor approved for IBS-C as Ibsrela, but Ardelyx is still seeking a commercial partner for that indication – and is maintaining focus on same molecule in hyperphosphatemia.
US FDA Reviews IBS-C Candidates Both New (Tenapanor) And Old (Tegaserod)
Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.
Deals Of The Week: AstraZeneca/Ardelyx, Roche/Inception, GlaxoSmithKline/Aeras
Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.